I am an accomplished senior pharmaceutical executive with more than 30 years of success across the biotech, pharmaceutical, and neuroscience industries. Leveraging extensive experience leading R&D organizations to achieve key milestones and guiding business development and key alliances to impact business goals, I have proven myself as a valuable asset for companies in the life sciences sector. My broad areas of expertise include drug metabolism and pharmacokinetics, R&D, business development, personnel development, operations, regulatory compliance, strategic alliances, risk management, and process improvement.
Throughout my executive career, I have held leadership positions at companies including Eli Lilly and Company and Johnson & Johnson. I recently moved into retirement following 17 years with Eli Lilly, concluding as senior director and COO from 2008 to 2017. I was instrumental in developing high-performance strategic alliances that helped drive revenue of more than $1.6 billion over 10 years, oversaw $110 million of spend on global externally sourced pharmaceutical discovery and development, and served as COO of neuroscience research and clinical development. This followed six years as senior director of preclinical drug metabolism and pharmacokinetics, where I managed more than 100 scientific personnel supporting R&D, drove integration of global research functions to increase productivity, and spearheaded improvements to reduce research cycle time and unit costs by 15%.
Over the last five years, I have provided pharmaceutical discovery and development expertise to small biotech and pharmaceutical companies. Additionally, I currently advise in academia, including through the Indiana CTSI Drug Development Think Tank and the IU Simon Comprehensive Cancer Cancer Drug Discovery & Development Accelerator (CD3A). My deep expertise in drug discovery and development in both small and large pharma allows me to advise researchers at the cancer center, supporting research projects and leading interdisciplinary project teams to drive effective decisions, including target selection, hit identification, lead optimization, and drug candidate identification. At Eli Lilly and Company, I oversaw the drug discovery and development of over 10 cancer research programs, providing drug metabolism and pharmacokinetic data as well as global regulatory submissions, including INDs and NDAs.
Key Milestone Expertise in Drug Discovery & Development:
- Lead Identification
- Lead Optimization
- Predevelopment (candidate selection)
- IND enabling
- Phase I-III trials
